To compare the curative effects of heat-sensitive moxibustion with conventional drugs on chronic persistent asthma and seek a valuable therapy to replace Western Medicine.
INTRODUCTION
Bronchial asthma is a significant burden on healthcare and the social economy. [1] [2] [3] [4] [5] In 2010, there were 300 million asthma patients worldwide. 6 At present, no single therapy can effectively cure it. Therefore, asthma treatment aims to control the disease and improve the quality of life. 7, 8 Western Medicine can cause discomfort and influence daily life. 9 Therefore, acupuncture or moxibustion has been gradually accepted as a complementary or alternative treatment in China and Western countries for preventing asthma attacks and relieving symptoms. [10] [11] [12] Heat-sensitive moxibustion is a new therapy in which a burning moxa-roll is placed over a heat-sensitive acupoint. 13 Studies have shown that it can treat diseases such as myofascial pain syndrome, 14 lumbar disc herniation, 15 pressure sores, 16 knee osteoarthritis, 17 primary dysmenorrhea, 18 neck pain, 19 and allergic rhinitis. 20 We have found that moxibustion over heat-sensitive acupoints on the back of asthma patients 21, 22 can improve their clinical asthma symptoms. 23, 24 Two trials suggesting that heat-sensitive moxibustion can treat asthma 23, 24 were not randomized and controlled trials with large sample sizes. Therefore, we designed this rigorous trial to provide evidence to confirm the curative effect of heat-sensitive moxibustion on chronic persistent asthma. Heat-sensitive moxibustion could be a valuable asthma-controlling therapy to replace Western Medicine. The designed plan of this study was published in Trials in October 2010. 25 
DATA AND METHODS

Estimation of sample size
We estimated the sample size according to the requirements of a non-inferiority clinical trial. Non-inferiority critical value δ was determined with a small sample pilot study. ACT score after 3 months of treatment was used as the terminal index. The difference in means between the two groups was 0.45. Considering clinical relevance and statistical judgment, δ=0.15 (30% of Δ). We calculated that 120 patients (α=0.05, β=0.2) were needed. Allowing for a 20% loss, 144 participants were required in each group, with 288 participants in total.
Randomization
Central randomization used in this trial was performed by the China Academy of Chinese Medical Sciences (Beijing, China). Patients meeting the inclusion criterion were randomly and equally divided into two groups. Before randomization, the patients gradually stopped medication and were routinely nursed for asthma.
Ethics
The ethics committee of the Hospital Affiliated to Jiangxi Institute of Traditional Chinese Medicine approved this trial with the code 2008 (13) .
Inclusion criterion
Patients meeting the asthma-diagnosing standard according to the guideline of asthma treatment and prevention in China (GATPC) 24 were grouped into three categories: acute exacerbation, chronic persistence, and clinical remission. GATPC severity includes intermittent, mild, moderate, and severe grades. Our trial only chose patients with chronic moderate persistent asthma. All patients aged 18-65 years provided written informed consent. Moreover, heat-sensitivity appeared within the rectangular area consisting of the two outer lines of the dorsal Bladder Meridian of Foot-Taiyang and two horizontal lines of Fei Shu (BL 13) and Geshu (BL 17), 6 inches from the intercostals space between the first rib and second rib of the anterior aspect of the chest. Patients were asked to take no medicine during the treatment and acknowledge acceptance of treatment and related inquiries 24 h before and after treatment.
Exclusion criterion
Patients with one of the following conditions were excluded: (a) other diseases that also cause breathlessness or dyspnea, such as bronchiectasis, cor pulmonale, pulmonary fibrosis, tuberculosis, pulmonary abscess, and chronic obstructive pulmonary disease; (b) pregnancy or lactation; (c) hormone-dependent patients, or patients using adrenal cortical hormone within 4 weeks of recruitment; (d) life-threatening complications, such as cerebrocardiovascular diseases, diseases of liver, kidney, and hematopoietic system; and (e) psychotic patients.
Baseline data
Two hundred and thirty of 518 patients in our trial from September 2008 to December 2010 were excluded from the study (Figure 1 ). According to the definition of intention-to-treat (ITT), the ITT population comprised 288 patients in the twelve hospitals. The groups were comparable in baseline characteristics (Table 1), including the objective parameters of age, sex, duration of asthma, and ACT scores. There were no statistically significant differences between the two groups (P>0.05).
Data collection
Assessors, who did not participate in the treatment and were blind to the allocation results, performed the outcome assessment. The statistician conducting the analyses remained blind to treatment group. Data were made public once they were summarized and analyzed.
Treatment
The treatment plan in this study was developed over a 3-month period. Patients were randomly divided into a heat-sensitive moxibustion group (treatment group) and a control group. In the treatment group, all acupoints were stimulated with the burning of moxa-sticks, 22 mm in diameter and 160 mm in length, (produced by Jiangxi Hospital of Traditional Chinese Medicine, China). Patients lay in a comfortable position with the moxibustion site fully exposed in a room at 24℃-30℃.
Heat-sensitive moxibustion
An ignited moxa-stick was held over the rectangular area consisting of two outer lines of the dorsal Bladder Meridian of Foot-Taiyang and two horizontal lines of Feishu (BL 13) and Geshu (BL 17), 6 inches from the intercostal space between the first rib and second rib of the anterior aspect of the chest. The burning moxa-stick was held about 3 cm from the skin to look for heat-sensitive acupoints. When patients felt the heat penetrating to deep tissue or spreading to the surrounding area or transmitting in a direction, the therapists marked the point as having a heat-sensitive phenomenon. Therapists attempted to find all heat-sensitive acupoints in each patient. Having found all heat-sensitive acupoints possible, therapists treated patients at the acupoint most sensitive to heat until the patient nearly felt the disappearance of the heat-sensitivity. The heat-sensitivity tended to decrease but could be still identified even at the end of treatment. After treatment, the therapist recorded the duration of moxibustion. During the first month, patients were treated once a day in the first 8 days and 12 times in the following 22 days. The treatment was given 15 times a month in the remaining two months.
Control group (Seretide)
Seretide Accuhaler (GlaxoSmithKline Plc, UK), containing fluticasone propionate and salmeterol xinafoate, is recommended by Global Initiative for Asthma (GINA) as a regular treatment of asthma. 26 In our trial, patients were treated with Seretide (salmeterol 50 μg/ fluticasone 250 μg) twice a day for 90 days.
Index of observation
ACT score, a primary index of observation, was measured before treatment and after 15, 30, 60, and 90 days of treatment. ACT, recommended by GINA in 2002, 7 is a validated and patient-completed measurement of asthma control comprising five questions on limitation of activity, difficulty in breathing, symptoms at night, use of drugs and frequency of attack over the previous four weeks. The questions are scored from 1 (worst) to 5 (best), and the ACT score is the sum of the responses, giving the maximum score of 25. The ACT in Chinese, provided by China Asthma Alliance in 2006, 26 was tested by Chinese researchers previously. Some studies suggested that the score system was useful for identifying patients in China. 27, 28 Secondary indexes of observation were forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF), and frequency of attack. All patients filled in asthma diaries during 3 weeks before randomization and every visit after randomization. In the diaries they documented the time of attack from beginning to end, the intensity, the frequency, and the associated symptoms during each asthma attack. Patients documented whether or not they took medicine during treatment periods. If they did, they were required to document its name and dosage, the time of administration, the time of the relief of the symptoms and the side-effects of the medicine. Adverse reactions were recorded during the 3-month treatment and 6-month follow-up visit.
Quality monitoring
Monitoring the quality of moxibustion is mainly based on quality control program (QCP) including the design of case report form (CRF) and the training of qualified investigators, researchers and data-managers. 29 According to good clinical practice (GCP), a standard QCP was established to monitor the quality of our trial. Monitors directly appointed by the project leader completed the quality control program, guaranteed data accuracy, and prevented or detected plan violations. Clinical centers and clinicians, the randomization system of the centers, and the treatment processes were monitored. In addition, the case report forms were reviewed for completeness and internal consistency, the eligibility and validity of the patients in the study were verified, and data were monitored for compliance and accuracy.
Compliance analysis
In the control group, data were collected with an electronic timed inhaler (Nebulizer Chronolog), which can automatically count and record each actual inhaled dosage. The testees were given an initialized Nebulizer Chronolog and a diary card used to record their daily symptoms. The card included instructions on how to use the inhaler. After 3 months of treatment, the Nebulizer Chronolog and diary cards were returned. Days of good compliance were defined as days a patient took a fixed dosage of drug at the appropriate time.
Patients' compliance to receiving heat-sensitive moxibustion was assessed with three oral questions: "Does the patient receive moxibustion treatment in hospital regularly?" "Has the patient ever had any history of not using moxibustion treatment?" "Does the patient still receive last prescribed moxibustion?" The higher the score, the better the compliance.
Statistical analysis
The intention-to-treat (ITT) population is defined as the randomized patients. The data analysis of baseline characteristics is based on the ITT population as well as the primary and secondary indexes. In the ITT population, none of the patients were excluded and the patients were analyzed according to the randomization scheme. The basic ITT principle was that patients in the trials should be analyzed, regardless of whether they receive or adhere to treatment. Data were analyzed with SAS 9.0 statistical software (Cary, NC, USA). The first step of analysis was to compare baseline characteristics between the two groups. The second step was to check whether the treatment group was inferior or not to the control group in treating asthma. For data in a normal distribution (normality, homogeneity of variances), repeated analyses were used in assessments. Mann-Whitney U, t-test, and Wilcoxon test were used for comparison of variables. Two-sided test was applied to all available data, and P value <0.05 was considered statistically significant. Missing data were replaced according to the principle of the last observation.
RESULTS
ACT score
There was an obvious difference (P<0.001) in ACT score at each time-point as compared to baseline. Comparisons of data at six time-points between groups were multiple testing. We used the Bonferroni adjustment t-test. 30 The differences in ACT score between the two groups at each time-point are shown in Table 2 , indicating significant differences in the ACT score after 3 months of treatment (P=0.0002) and highly significant difference during the 6-month follow-up visit (P= 0.000 03). Figure 2 shows that the mean ACT score of both groups increased sharply after half a month of treatment and continually increased up to the end of 6-month follow-up visit. In the control group, the ACT score remained stable during 3-and 6-month follow-up visit, and patients continued to take the drug with gradually reduced dosage during follow-up visit. Tables 3 and Table 4 show the secondary indexes of FEV1, PEF, and attack frequency derived from ITT analyses. FEV1 and PEF in both groups after 3 months of treatment were much higher than those before treatment (Table 3 ). The improvement of lung function in the heat-sensitive moxibustion group was better than that in the control group (P=0.035 for FEV1, P=0.011 for PEF). Moreover, there were noticeable differences between the two groups during the 6-month follow-up visit (P=0.042 for FEV1, P=0.0012 for PEF). The frequency of asthma attack after 3 months of treatment in the heat-sensitive moxibustion group was much lower than that in the control group (P=0.000 17). There was still an obvious difference between the two groups during 6-month follow-up visit (P=0.047). In the control group, the majority of patients were able to correctly use the inhaler. The days of inhaling inadequate dosage accounted for 9% and the days of inhaling excessive dosage accounted for 2%. In the heat-sensitive moxibustion group, 90% of patients were regularly treated in hospitals, and only 1.5% of patients were irregularly treated. Adverse reactionsAmong the 9 patients (5.1% ) with mild adverse reactions during treatment were 5 cases of headache and 4 cases of palpitation. However, after the treatment, all the symptoms disappeared. No patient reported any severe adverse reactions.
Lung function
DISCUSSION
This trial used subjective and objective indexes to as-sess curative effect on asthma using standard treatment or heat-sensitive moxibustion. ACT score was markedly enhanced in both groups, there was an obvious difference in ACT score and lung function between the two groups, and asthma attack frequency was noticeably lower in the heat-sensitive moxibustion group. This indicates that heat-sensitive moxibustion is not inferior to Seretide in curative effect on bronchial asthma.
In contrast to acupuncture, heat-sensitive moxibustion indirectly stimulates acupoints. Adverse reactions, such as infection, minor hemorrhage and pain in the moxibustion region, and uncomfortable reactions, such as dizziness, nausea or vomiting, aggravation of complaint, malaise, fever and numbness, were not observed in the heat-sensitive moxibustion group. Meanwhile, several patients in the control group had adverse reactions. The most common adverse reactions to Seretide are upper respiratory tract infection, mouth infection, nausea, headache, muscle and bone pain, and bronchitis. 31, 32 The superiority of heat-sensitive moxibustion is manifested in its safety. Large-scale surveys have provided evidence that moxibustion is a relatively safe treatment. 33 To our knowledge, this is the first randomized controlled trial with large sample to compare the curative effect of heat-sensitive moxibustion and Western Medicine on asthma. Published studies have methodological deficiencies, including deficient randomization descrip- Notes: experimental group was treated with heat-sensitive moxibustion; control group was treated with fluticasone/salmeterol (Seretide). ACT: asthma control test. Bonferroni adjustment t-test was used for group differences. The adjusting of P-values was 0.008. Months tions, no concealment of therapeutic plan, data heterogeneity between groups, and different periods of follow-up visits. Unlike previous studies on moxibustion, our study required participating therapists to have corresponding medical education and TCM clinical practice before performing treatment according to a series of strict standards. In addition, our study used central randomization to ensure adequate concealment of group assignment. Both evaluation and statistical analysis were carried out blindly. High quality follow-up visits were an important guarantee for the quality of our trial. However, it was impossible for doctors to conduct a blind manipulative intervention method in this study. Zhao et al 34 has developed a moxa cone fixed to a special base to carry out sham or real moxibustion. Sham moxibustion is identical to real moxibustion in the shape, burning process, and residue of moxa cone but distinct in only the production of heat and smoke and isolation from skin. Of course, such a method is suitable for direct moxibustion. It is necessary for experienced therapists to carry out heat-sensitive moxibustion, an indirect moxibustion. Furthermore, it is very easy for bronchial asthma patients to distinguish heat-sensitive moxibustion from Seretide. However, it is possible for patients to carry out a blind method. Acupoints unrelated to asthma treatment can be selected for sham moxibustion in the control group. Meanwhile, a placebo could be taken in real moxibustion group. We intended to try the blind method in future trials. In our trial, we selected acupoints in the back, which are used to treat bronchial asthma and other lung diseases according to TCM theory. For example, Fei Shu (BL 13) on the Bladder Meridian of Foot-Taiyang, is used to treat bronchitis, asthma, pleurisy, and night sweating and can regulate lung Qi, improve lung function, and build Stomach Qi. Some experimental studies have indicated that the mechanism of moxibustion may be related to adjusting the release of inflammatory substances in the lung, improving respiratory tract spasms, and inhibiting respiratory tract inflammation. [33] [34] [35] A study of 32 patients with both asthma and rheumatoid arthritis showed the effects of acupuncture and moxibustion on immunoglobulin. 36, 37 A study in 1995 of 94 patients with bronchial asthma showed that acupuncture and moxibustion can affect the nervous and immune systems, cause metabolic changes, and effectively reduce the sensitivity and reactivity of bronchioles. In other words, acupuncture and moxibustion can reduce the reactivity of bronchioles to asthma-inducing factors. 37, 38 Although studies from China have investigated the mechanisms of moxibustion on the nervous system, 39 further study is still necessary. Because adverse reactions caused by long-term use of asthma drugs can influence their continuous use, other treatment courses are necessary. This study has demonstrated that the curative effect of heat-sensitive moxibustion is not inferior to that of Seretide on asthma. Therefore, our study has clinical significance for providing a potential non-drug therapy to control asthma. Notes: experimental group was treated with heat-sensitive moxibustion; control group was treated with fluticasone/salmeterol (Seretide).
